

Reflections

July 2021

The political and regulatory backdrop in China (and elsewhere!) has always ebbed and flowed. Our approach to identifying which companies will have the best chance of transformational growth over the next five to 10 years is, as always, based on bottom-up fundamental analysis – and this remains the case even as the regulatory backdrop evolves.

Our experience in China has been that the regulatory issues are usually about the balance between societal stability on the one hand, and technological innovation for prosperity on the other. Alignment of both clearly matters to the state. At times innovation might run ahead of stability, or vice versa, so regulation is used to restore balance.

We believe it is important to draw a distinction between matters of national security, data privacy and antitrust regulations, as opposed to the politics of listing. There are both push and pull factors associated with the listing venue of choice. China wants its companies to list on domestic exchanges as this aligns with its long-term ambition to shift the balance of global liquidity and capital market traffic, while the US's hard line on audit data currently means Chinese ADRs may have a limited lifespan. This is consistent with our view of the broad direction of travel over the past few years. In the first instance we would expect to see a growing number of secondary listings from US ADRs in Hong Kong.

If Chinese companies opt to list in China rather than the ADR route, we're well positioned as a firm to manage this – thanks in part to our Hong Kong-based dealing desk, our Shanghai research office, and our experience investing in HK lines and China A Shares. Within the LTGG portfolio there are 10 Chinese names, eight of these are held as ADRs. Many have dual listing status and we are considering switching to the Hong Kong line where possible. This is a straightforward process – executing the right to have the shares exchanged – and has minimal cost. For those holdings without local listings we have engaged to ensure they are managing the situation and have plans in place.

Perhaps the more important analysis, certainly to us, is assessing whether the companies in which we invest are well positioned to navigate regulatory developments. We therefore consider how material such developments may be in the context of our investment thesis for each individual company. We have been here before with Baidu and healthcare advertising, Tencent and the gaming approval suspension and more recently with Ant Financial.





Very often we find that the companies in which we invest are in fact well-aligned with the interests of the state. Regulation of the ecommerce sector, for example, has been more focused on creating a level playing field for consumers, merchants, and employees. This probably enhances the long-term opportunity. Chinese growth is driven by small and medium-sized enterprises (SMEs) and the big platforms found within the LTGG portfolio enable these SMEs.

More recent regulation centred around education reform is perhaps something new. So why focus on this sector? The Chinese government was shocked by the recent census that showed the country was aging faster than expected. This was met with a relaxation of the one child policy. The new three child policy was greeted on social media by 'I can barely afford one child, let alone three'.

Three of the largest costs to Chinese families are education, housing and healthcare. Consequently, it is likely that these three sectors may be in the firing line to raise birth rates. The three names therefore more in focus for LTGG are TAL Education, KE Holdings and BeiGene.

Given the desire to reduce education costs there is some surprise that TAL has been affected by the regulatory drive given one of its avowed aims is to lower education costs by using technology. Our worst-case scenario based on the current proposals is that TAL's revenues and profits reset at about half of their previous levels which would be more than accounted for by the recent share price fall. We are due to meet management in early August and will be conducting a full 10Q review.

On housing, KE Holdings has been subject to rumours, but in fact this company has done more to establish industry standards in the real estate market than any other. So, despite short-term volatility, we believe the long-term outlook remains positive. Within healthcare, regulation over the past five years has been updated to encourage innovation and we don't believe regulators will change course meaning innovating companies such as BeiGene should be fine, whereas generics companies may be vulnerable to greater price controls.

We continue to monitor and engage with LTGG companies as we calibrate our probability-adjusted upside scenarios for your Chinese holdings, and we will be pleased to provide further updates in due course. In terms of tone in the team at this point though, we are quite likely to be embracing opportunities to add to holdings where their share prices have become disconnected from their fundamentals.

Important information and risk factors

Past performance is not a guide to future results. Changes in the investment strategies, contributions or withdrawals may materially alter the performance and results of the portfolio. All investment strategies have the potential for profit and loss.

Risk factors

The views expressed in this article are those of the authors and should not be considered as advice or a recommendation to buy, sell or hold a particular investment. They reflect personal opinion and should not be taken as statements of fact nor should any reliance be placed on them when making investment decisions.

Any stock examples and images used in this article are not intended to represent recommendations to buy or sell, neither is it implied that they will prove profitable in the future. It is not known whether they will feature in any future portfolio produced by us. Any individual examples will represent only a small part of the overall portfolio and are inserted purely to help illustrate our investment style.

This article contains information on investments which does not constitute independent research. Accordingly, it is not subject to the protections afforded to independent research, but is classified as advertising under Art 68 of the Financial Services Act ('FinSA') and Baillie Gifford and its staff may have dealt in the investments concerned.

All information is sourced from Baillie Gifford & Co and is current unless otherwise stated. The images used in this article are for illustrative purposes only.

Important information

Baillie Gifford & Co and Baillie Gifford & Co Limited are authorised and regulated by the Financial Conduct Authority (FCA). Baillie Gifford & Co Limited is an Authorised Corporate Director of OEICs.

Baillie Gifford Overseas Limited provides investment management and advisory services to non-UK Professional/Institutional clients only. Baillie Gifford Overseas Limited is wholly owned by Baillie Gifford & Co. Baillie Gifford & Co and Baillie Gifford Overseas Limited are authorised and regulated by the FCA in the UK.

Persons resident or domiciled outside the UK should consult with their professional advisers as to whether they require any governmental or other consents in order to enable them to invest, and with their tax advisers for advice relevant to their own particular circumstances.

Baillie Gifford Investment Management (Europe) Limited provides investment management and advisory services to European (excluding UK) clients. It was incorporated in Ireland in May 2018 and is authorised by the Central Bank of Ireland. Baillie Gifford Investment Management (Europe) Limited provides investment management and advisory services to European (excluding UK) clients. It was incorporated in Ireland in May 2018 and is authorised by the Central Bank of Ireland. Through its MiFID passport, it has established Baillie Gifford Investment Management (Europe) Limited (Frankfurt Branch) to market its investment management and advisory services and distribute Baillie Gifford Worldwide Funds plc in Germany.

Similarly, it has established Baillie Gifford Investment Management (Europe) Limited (Amsterdam Branch) to market its investment management and advisory services and distribute Baillie Gifford Worldwide Funds plc in The Netherlands. Baillie Gifford Investment Management (Europe) Limited also has a representative office in Zurich, Switzerland pursuant to Art. 58 of the Federal Act on Financial Institutions ('FinIA'). It does not constitute a branch and therefore does not have authority to commit Baillie Gifford Investment Management (Europe) Limited. It is the intention to ask for the authorisation by the Swiss Financial Market Supervisory Authority (FINMA) to maintain this representative office of a foreign asset manager of collective assets in Switzerland pursuant to the applicable transitional provisions of FinIA. Baillie Gifford Investment Management (Europe) Limited is a wholly owned subsidiary of Baillie Gifford Overseas Limited, which is wholly owned by Baillie Gifford & Co.

Hong Kong

Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港) 有限公司 is wholly owned by Baillie Gifford Overseas Limited and holds a Type 1 and a Type 2 licence from the Securities & Futures Commission of Hong Kong to market and distribute Baillie Gifford's range of collective investment schemes to professional investors in Hong Kong. Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港) 有限公司 can be contacted at Suites 2713-2715, Two International Finance Centre, 8 Finance Street, Central, Hong Kong. Telephone *852 3756 5700.

South Korea

Baillie Gifford Overseas Limited is licensed with the Financial Services Commission in South Korea as a cross border Discretionary Investment Manager and Non-discretionary Investment Adviser.

Japan

Mitsubishi UFJ Baillie Gifford Asset Management Limited ('MUBGAM') is a joint venture company between Mitsubishi UFJ Trust & Banking Corporation and Baillie Gifford Overseas Limited. MUBGAM is authorised and regulated by the Financial Conduct Authority.

Australia

Baillie Gifford Overseas Limited (ARBN 118 567 178) is registered as a foreign company under the Corporations Act 2001 (Cth) and holds Foreign Australian Financial Services Licence No 528911. This document is provided to you on the basis that you are a 'wholesale client' within the meaning of section 761G of the Corporations Act 2001 (Cth) ('Corporations Act'). Please advise Baillie Gifford Overseas Limited immediately if you are not a wholesale client. In no circumstances may this document be made available to a 'retail client' within the meaning of section 761G of the Corporations Act.

This document contains general information only. It does not take into account any person's objectives, financial situation or needs.

Important information and risk factors

South Africa

Baillie Gifford Overseas Limited is registered as a Foreign Financial Services Provider with the Financial Sector Conduct Authority in South Africa.

North America

Baillie Gifford International LLC is wholly owned by Baillie Gifford Overseas Limited; it was formed in Delaware in 2005 and is registered with the SEC. It is the legal entity through which Baillie Gifford Overseas Limited provides client service and marketing functions in North America. Baillie Gifford Overseas Limited is registered with the SEC in the United States of America.

The Manager is not resident in Canada, its head office and principal place of business is in Edinburgh, Scotland. Baillie Gifford Overseas Limited is regulated in Canada as a portfolio manager and exempt market dealer with the Ontario Securities Commission ('OSC'). Its portfolio manager licence is currently passported into Alberta, Quebec, Saskatchewan, Manitoba and Newfoundland & Labrador whereas the exempt market dealer licence is passported across all Canadian provinces and territories. Baillie Gifford International LLC is regulated by the OSC as an exempt market and its licence is passported across all Canadian provinces and territories. Baillie Gifford Investment Management (Europe) Limited ('BGE') relies on the International Investment Fund Manager Exemption in the provinces of Ontario and Quebec.

Israel

Baillie Gifford Overseas is not licensed under Israel's Regulation of Investment Advising, Investment Marketing and Portfolio Management Law, 5755–1995 (the Advice Law) and does not carry insurance pursuant to the Advice Law. This document is only intended for those categories of Israeli residents who are qualified clients listed on the First Addendum to the Advice Law.

Oman

Baillie Gifford Overseas Limited ('BGO') neither has a registered business presence nor a representative office in Oman and does not undertake banking business or provide financial services in Oman. Consequently, BGO is not regulated by either the Central Bank of Oman or Oman's Capital Market Authority. No authorization, licence or approval has been received from the Capital Market Authority of Oman or any other regulatory authority in Oman, to provide such advice or service within Oman. BGO does not solicit business in Oman and does not market, offer, sell or distribute any financial or investment products or services in Oman and no subscription to any securities, products or financial services may or will be consummated within Oman. The recipient of this document represents that it is a financial institution or a sophisticated investor (as described in Article 139 of the Executive Regulations of the Capital Market Law) and that its officers/employees have such experience in business and financial matters that they are capable of evaluating the merits and risks of investments.

Qatar

The materials contained herein are not intended to constitute an offer or provision of investment management, investment and advisory services or other financial services under the laws of Qatar. The services have not been and will not be authorised by the Qatar Financial Markets Authority, the Qatar Financial Centre Regulatory Authority or the Qatar Central Bank in accordance with their regulations or any other regulations in Qatar.



Calton Square, 1 Greenside Row, Edinburgh EH1 3AN Telephone *44 (0)131 275 2000 / bailliegifford.com